Takeda Y, Kubota N, Nishio K, Funayama Y, Gemma A, Niitani H, Saijo N
NATL CANC CTR,RES INST,DIV PHARMACOL,CHUO KU,TOKYO 104,JAPAN. NIPPON MED COLL,DEPT INTERNAL MED 4,BUNKYO KU,TOKYO 104,JAPAN.
Oncol Rep. 1995 Sep;2(5):705-10. doi: 10.3892/or.2.5.705.
We report on a human small cell lung cancer subline (H69/OA100) resistant to okadaic acid, an inhibitor of protein phosphatases. H69/OA100 showed cross-resistance to cis-diamminedichloroplatinum(II) (CDDP), adriamycin, and vinca alkaloids. Intracellular retention of adriamycin and CDDP in H69/OA100 was the same as those in H69. H69/OA100 was not shown to express MDR-1 by the reverse transcription polymerase chain reaction method. Expression level of mRNA of multidrug resistance-associated protein (MRP) in H69/OA100 was the same as that in H69. These data suggest that the mechanism of drug resistance in H69/OA100 might be due to a new mechanism of non-P-glycoprotein mediated multidrug resistance.
我们报告了一株对冈田酸（一种蛋白磷酸酶抑制剂）具有抗性的人小细胞肺癌亚系（H69/OA100）。H69/OA100对顺二氨二氯铂（II）（CDDP）、阿霉素和长春花生物碱表现出交叉抗性。阿霉素和CDDP在H69/OA100细胞内的滞留情况与在H69细胞中相同。通过逆转录聚合酶链反应法未显示H69/OA100表达MDR-1。多药耐药相关蛋白（MRP）在H69/OA100中的mRNA表达水平与在H69中相同。这些数据表明，H69/OA100中的耐药机制可能归因于一种新的非P-糖蛋白介导的多药耐药机制。
